Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
deals
fda
3
×
life sciences
national blog main
alexion pharmaceuticals
boston
boston blog main
boston top stories
achaogen
adams street partners
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
antibiotics
autoimmune disorders
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boehringer ingelheim
complement system
dicerna pharamceuticals
drug resistance
drugs
generalized myasthenia gravis
hatteras venture partners
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
immune-mediated necrotizing myopathy
investing
lyzz capital
macrolide pharmaceuticals
melinta therapeutics
meropenem
michael dudley
national top stories
new enterprise associates
new york blog main
patisiran
ra pharmaceuticals
What
disease
3
×
drug
medicines
3
×
pharma
pharmaceuticals
alternative
autoimmune
bacteria
biopharma
business
candidate
caught
causing
company
deal
dicerna
exited
expensive
eye
fighting
gene
hepatitis
infections
infectious
intended
launches
lead
melinta
pay
potential
producing
products
protein
qpex
ra
research
resistant
roche
sold
stakes
Language
unset
Current search:
fda
×
medicines
×
disease
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
